[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"duchenne-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:duchenne-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":5},"100538429","phase-2-vasodilator-and-exercise-study-for-dmd-vaso-rex-100538429",false,"NCT06290713","Vasodilator and Exercise Study for DMD (VASO-REx)","Vasodilators and Exercise as Adjuvant Therapy for Duchenne Muscular Dystrophy (VASO-REx Study)","Inclusion Criteria:\n\n* Diagnosis of DMD confirmed by genetic report\n* Minimum entry age of 6.0 years old\n* Ambulatory\n* On stable glucocorticoid regimen (for \\> 3 months)\n\nExclusion Criteria:\n\n* Contraindication to a Magnetic resonance Imaging examination (e.g. severe claustrophobia, magnetic implants, unable\u002Funwilling to perform test)\n* Presence of unstable medical problems, including severe cardiomyopathy, left ventricular ejection fraction \\\u003C45%, cardiac conduction abnormalities as evidenced on ECG, uncontrolled seizure disorder, uncontrolled hypo or hypertension\n* Presence of a secondary condition that impacts muscle function or muscle metabolism (e.g., myasthenia gravis, endocrine disorder, mitochondrial disease)\n* Presence of a secondary condition leading to developmental delay or impaired motor control (e.g., cerebral palsy) or previous history of unprovoked rhabdomyolysis\n* Contraindications to phosphodiesterase 5 inhibitors (use of nitrates, alpha-adrenergic blockers, other phosphodiesterase 5 inhibitors) or other medications known to modulate blood flow or muscle metabolism\n* Participation in currently approved FDA trials or other investigational clinical trials during the period of the study","MALE","6 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Examining two strategies as potential adjuvant therapies for Duchenne muscular dystrophy (DMD); aerobic exercise training (to induce adaptations in skeletal muscle and improve cardiovascular health) and tadalafil, an FDA-approved vasodilator (to optimize blood flow and muscle perfusion which is impaired and often overlooked in DMD). Target: improved muscle function, vascular health, and DMD treatment.",[26,27,28,29,30,31,32],"Duchenne Muscular Dystrophy","Duchenne Disease","Muscular Dystrophy","Muscular Dystrophy in Children","Vasodilation","Exercise","DMD",[32,34,35,36],"Tadalafil","Drug and Exercise Intervention","Treatment Strategy","RECRUITING","2026-05-12",{"date":40,"type":41},"2026-05-15","ACTUAL",{"date":43,"type":41},"2024-06-05",{"date":45,"type":20},"2026-11",{"name":47,"class":48},"University of Florida","OTHER"]